Shots:
- Hansa has granted SERB exclusive development & commercialisation rights to Idefirix (imlifidase) in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland & the MENA region
- As per the deal, Hansa will receive €110M upfront & an additional €5M upon acceptance of the full approval filing for Idefirix by the EMA. Hansa will also support SERB in the filing & EMA review process following topline data from the Post-Authorization Efficacy Study (PAES) study
- SERB will assume responsibility for the long-term PAES follow-up & ongoing pediatric study for Idefirix upon becoming MAH, with the process expected to begin immediately after transaction closing
Ref: Globenewswire | Image: Hansa & SERB | Press Release
Related News: SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for ~$412M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
